NCT00702221View on ClinicalTrials.gov

Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2010

Conditions
HypertensionCardiovascular Disease
Interventions
BIOLOGICAL

Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant

Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart

BIOLOGICAL

CoVaccine HT™ adjuvant

Given as three separate intramuscular injections into the arm, 21 days apart

Trial Locations (12)

PL23 1DT

Fowey River Practice, Fowey

TR18 4JH

Alverton Practice, Penzance

PL26 7RL

Brannel Surgery, Saint Stephen

PL12 6DL

Saltash Health Centre, Saltash

TR19 7HX

Cape Cornwall Surgery, St Just

S40 4FT

Avondale Surgery, Chesterfield

PL5 3JB

Knowle House Surgery, Plymouth

FY3 7EN

Layton Medical Centre, Blackpool

CV32 4RA

Sherbourne Medical Centre, Royal Leamington Spa

SN25 4YZ

Abbey Meads Medical Practice, Swindon

WR7 4BW

Grey Gable Surgery, Inkberrow

M50 2GY

The Acumen Pharmaceutical Services Ltd, Manchester

Sponsors

Collaborators (1)

Encorium
All Listed Sponsors
collaborator

Encorium

INDUSTRY

lead

BTG International Inc.

OTHER